Pharmacogenetic insights into codeine analgesia: Implications to pediatric codeine use

Pharmacogenomics

Volumn 9, Issue 9, 2008, Pages 1267-1284

  Madadi, Parvaz ^a   Koren, Gideon ^a,b,c  

^a WESTERN UNIVERSITY   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

opioid receptor; Adverse drug reactions; Breastfeeding; Codeine; CYP2D6; Morphine; Ontogeny; P glycoprotein; Pediatrics; UGT2B7

Indexed keywords

CODEINE; CYTOCHROME P450 2D6; DICLOFENAC; DRUG METABOLITE; EPIRUBICIN; GLUCURONOSYLTRANSFERASE 2B7; HYDROXYUREA; MORPHINE; MORPHINE SULFATE; MU OPIATE RECEPTOR; MYCOPHENOLIC ACID; NALOXONE; OPIATE; PARACETAMOL; PLACEBO; TRAMADOL;

ABDOMINAL PAIN; AGITATION; ANALGESIA; APNEA; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN METABOLISM; BREAST FEEDING; BREATHING DISORDER; CANCER PAIN; CLINICAL TRIAL; COMA; CONSTIPATION; COUGHING; CYANOSIS; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG TRANSPORT; DRUG USE; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME SPECIFICITY; EUPHORIA; FACE EDEMA; FEEDING DISORDER; GENE DUPLICATION; GENE MUTATION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HYPOTENSION; HYPOXIA; LETHARGY; LIVER METABOLISM; LIVER TOXICITY; MUSCLE HYPOTONIA; MUSCLE RIGIDITY; NAUSEA AND VOMITING; NERVOUSNESS; NEUROTOXICITY; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PRESCRIPTION; PUPIL DISEASE; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; SEDATION; SICKLE CELL ANEMIA; SIDE EFFECT; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISCOLORATION; SOMNOLENCE; TONIC SEIZURE; UNCONSCIOUSNESS; UNSPECIFIED SIDE EFFECT; WEAKNESS; XEROSTOMIA;

AGE FACTORS; ANALGESIA; CHILD; CODEINE; HUMANS; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; PHARMACOGENETICS;

EID: 55649094298     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.9.1267     Document Type: Review

References (150)

1. de Lima J, Lloyd-Thomas AR, Howard RF, Sumner E, Quinn TM: Infant and neonatal pain: anaesthetists' perceptions and prescribing patterns. BMJ313(7060), 787 (1996).
2. Codeine for child pain: new preparation. Helpful in some cases. Prescrire Int. 8(42), 107-109 (1999).
3. Conroy S, Peden V: Unlicensed and off label analgesic use in paediatric pain management. Paediatr. Anaesth. 11(4), 431-436 (2001).
4. William DG, Hatch DJ, Howard RF: Codeine phosphate in paediatric medicine. Br. J. Anaesth. 86(3), 413-421 (2001).
5. World Health Organization: Cancer Pain Relief. WHO, Geneva, Switzerland (1986).
6. Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC: Efficacy and safety of nonsteroidal anti-inflammatory drugs for cancer pain: a meta-analysis. J. Clin. Oncol. 12(12), 2756-2765 (1994).
7. Chen ZR, Irvine RJ, Somogyi AA, Bochner F: μ receptor binding of some commonly used opioids and their metabolites. Life Sci. 48(22), 2165-2171 (1991).
8. Coffman BL, Rios GR, King CD, Tephly TR: Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab. Dispos. 25(1), 1-4 (1997).
9. Chen ZR, Somogyi AA, Reynolds G, Bochner F: Disposition and metabolism of codeine after single and chronic doses in one poor and seven extensive metabolisers. Br. J Clin. Pharmacol. 31(4), 381-390 (1991).
10. Yoe QY, Hasselstrom J, Svensson JO, Sawe J: Pharmarokinetics of codeine and its metabolites in Caucasian healthy volunteers: comparisons between extensive and poor hydroxylators of debrisoquine. Br. J. Clin. Pharmacol. 31(6), 635-642 (1991).
11. Srinivasan V, Wielbo D, Tebbett IR: Analgesic effects of codeine-6-glucuronide after intravenous administration. Eur. J. Pain 1(3), 185-190 (1997).
12. Lotsch J, Skarke C, Schmidt H et al.: Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites. Clin. Pharmacol. Ther. 79(1), 35-48 (2006).
13. Caraco Y, Tateishi T, Guengerich FP, Wood AJ: Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity. [i Drug Metab. Dispos. 24(7), 761-764 (1996).
14. Cone EJ, Darwin WD, Gorodetzky CW: Comparative metabolism of codeine in man, rat, dog, guinea-pig and rabbit: identification of four new metabolites. J. Pharm. Pharmacol. 31(5), 314-317 (1979).
15. Oyler JM, Cone EJ, Joseph RE Jr, Huestis MA: Identification of hydrocodone in human urine following controlled codeine administration. J. Anal. Toxicol. 24(7), 530-535 (2000).
16. Milne RW, Nation RL, Somogyi AA: The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab. Rev. 28(3). 345-472 (1996).
17. Wittwer E, Kern SE: Role of morphine's metabolites in analgesia: concepts and controversies. AAPS J. 8(2), E348-E352 (2006).
18. Stone AN, Mackenzie PI, Galetin A, Houston JB, Miners JO: Isoform selectivity and kinetics of morphine' 3- and 6-glucuronidation by human UDP- glucuronosyltransferases: evidence for atypical glucuronidation kinetics by UGT2B7. Drug Metab. Dispos. 31(9), 1086-1089 (2003).
19. Nagano E, Yamada H, Oguri K: Characteristic glucuronidation pattern of physiologic concentration of morphine in rat brain. Life Sci. 67(20), 2453-2464 (2000).
20. Donnerer J, Cardinale G, Coffey J, Lisek CA, Jardine I, Spector S: Chemical characterization and regulation of endogenous morphine and codeine in the rat. J. Pharmacol. Exp. Ther. 242(2), 583-587 (1987).
21. Gong QL, Hedner J, Bjorkman R, Hedner T: Morphine-3-glucuronide may functionally antagonize morphine-6-glucuronide induced antinociception and ventilatory depression in the rat. Pain 48(2), 249-255 (1992).
22. Skarke C, Darimont J, Schmidt H, Geisslinger G, Lotsch J: Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers. Clin. Pharmacol. Ther. 73(1), 107-121 (2003).
23. Crooks PA, Kottayil SG, AlGhananeem AM, Byrn SR, Allan Butterfield D: Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg. Med. Chem. Lett. 16(16), 4291-4295 (2006).
24. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE: Developmental pharmacology - drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349(12), 1157-1167 (2003).
25. Eckhardt K, Li S, Ammon S, Schanzie G, Mikus G, Eichelbaurn M: Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation. Pain 76(1-2), 27-33 (1998).
26. Sindrup SH, Brosen K: The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics 5(6), 335-346 (1995).
27. Yue QY, Alm C, Svensson JO, Sawe J: Quantification of the O- and N-demethylated and the glucuronidated metabolites of codeine relative to the debrisoquine, metabolic ratio in urine in ultrarapid, rapid, and poor debrisoquine hydroxylators. Ther. Drug Monit. 19(5), 539-542 (1997).
28. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C: Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol. Ther. 116(3), 496-526 (2007).
29. Steimer W, Zopf K, von Amelunxen S et al.: Allele-specific change of concentration and functional gene dose for the predection steady-state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin. Chem. 50(9), 1623-1633 (2004).
30. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS: The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin. Pharmacol. Ther. 83(2), 234-242 (2008).
31. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S: CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet. Genomics 17(2), 93-101 (2007).
32. Dalen P, Dahl ML, Eichelbaum M, Bertilsson L, Wilkinson GR: Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes. Pharmacogenetics 9(6), 697-706 (1999).
33. Kirchheiner J, Schmidt H, Tzvetkov M et al.: Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics 7(4), 257-265 (2007).
34. Dalen P, Frengell C, Dahl ML, Sjoqvist F: Quick onset of severe abdominal pain after codeine in an ultrarapid metabolizer of debrisoquine. Ther. Drug Monit. 19(5), 543-544 (1997).
35. Gasche Y, Daali Y, Fathi M et al.: Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N. Engl. J. Med. 351(27), 2827-2831 (2004).
36. Koren G, Cairns J, Chitayat D, Gaedigk A, Leeder SJ: Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet 368(9536), 704 (2006).
37. Madadi P, Koren G, Cairns J et al.: Safety of codeine during breastfeeding: fatal morphine poisoning in the breasfed neonate of a mother prescribed codeine. Can. Fam. Physician. 53(1), 33-35 (2007).
38. Voronov P, Przybylo HJ, Jagannathan N: Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer. Paediatr. Anaesth. 17(7), 684-687 (2007).
39. de Leon J: CYP2D6 genotyping and codeine. Paediatr. Anaesth. 18(3), 274-275; author reply 275-276 (2008).
40. de Wildt SN, Koren G: Re: Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer [corrected]. Paediatr. Anaesth. 18(3), 273-274; author reply 275-276 (2008).
41. Stamer UM, Stuber F: Codeine induced respiratory depression in a child. Paediatr. Anaesth. 18(3), 272-273; author reply 275-276 (2008).
42. Lotsch J, Skarke C, Liefhold J, Geisslinger G: Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin. Pharmacokinet. 43(14), 983-1013 (2004).
43. Susce MT, Murray-Carmichael E, de Leon J: Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer. Prog. Neuropsychopharmacol. Biol. Psychiatry. 30(7), 1356-1358 (2006).
44. Ladona MG, Lindstrom B, Thyr C, Dun-Ren P, Rane A: Differential foetal development of the O- and N-demethylation of codeine and dextromethorphan in man. Br. J. Clin. Pharmacol. 32(3), 295-302 (1991).
45. Stevens JC, Marsh SA, Zaya MJ, Regina KJ, Le M, Hines RN: Developmental changes in human liver CYP2D6 expression. Drug Metab. Dispos. 36(8), 1587-1593 (2008).
46. Treluyer JM, Jacqz-Aigrain E, Alvarez F, Cresteil T: Expression of CYP2D6 in developing human liver. Eur. J. Biochem. 202(2), 583-588 (1991).
47. Jacqz-Aigrain E, Funck-Brentano C, Cresteil T: CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3(4), 197-204 (1993).
48. Johnson TN, Rostami-Hodjegan A, Tucker GT: Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45(9), 931-956 (2006).
49. Blake MJ, Gaedigk A, Pearce RE et al.: Ontogeny of dextromethorphan O- and N-demethylation in the first year of life. Clin. Pharmacol. Ther. 81(4), 510-516 (2007).
50. Allegaert K, van Schaik RH, Vermeersch S, et al.: Postmenstrual age and CTP2D6 polymorphisms determine tramadol O-demethylation in critically ill neonates and infants. Pediatr. Res. 63(6), 674-679 (2008).
51. Johnson TN, Tucker GT, Rostami-Hodjegan A: Development of CYP2D6 and CYP3A4 in the first ygar of life. Clin. Pharmacol. Ther. 83(5), 670-671 (2008).
52. Sarikaya D, Bilgen C, Kamataki T, Topcu Z: Comparative cytochrome P450 - 1A1, -2A6, -2B6, -2C, -2D6, -2EI, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA level. Biopharm. Drug Dispos. 27(8), 353-359 (2006).
53. Lash LH, Putt DA, Cai H: Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells. Toxicology 244(1), 56-65 (2008).
54. Guidice JM, Marez D, Sabbagh N et al.: Evidence for CYP2D6 expression in human lung. Biochem. Biophys. Res. Commun. 241(1), 79-85 (1997).
55. Siegle I, Fritz P, Eckhardt K, Zanger UM, Eichelbaum M: Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11 (3), 237-245 (2001).
56. Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF: Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J. Neurochem. 82(6), 1376-1387 (2002).
57. Gaedigk A, Gaedigk R, Leeder JS: CYP2D7 splice variants in human liver and brain: does CYP2D7 encode functional protein? Biochem. Biophys. Res. Commun. 336(4), 1241-1250 (2005).
58. Ohno S, Kawana K, Nakajin S: Contribution of UDP-glucuronosyltransferase 1A1 and 1A8 to morphine-6-glucuronidation and its kinetic properties. Drug Metab. Dispos. 36(4), 688-694 (2008).
59. Bhasker CR, McKinnon W, Stone A et al.: Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance. Pharmacogenetics 10(8), 679-685 (2000).
60. Jin C, Miners JO, Lillywhite KJ, Mackenzie PI: Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J. Pharmacol. Exp. Ther. 264(1), 475-479 (1993).
61. Ritter JK, Sheen YY, Owens IS: Cloning and expression of human liver UDP-glucuronosyltransferase in COS-1 cells. 3,4-catechol estrogens and estriol as primary substrates. J. Biol. Chem. 265(14), 7900-7906 (1990).
62. Holthe M, Klepstad P, Zahlsen K et al.: Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapy. Eur. J. Clin. Pharmacol. 58(5), 353-356 (2002).
63. Holthe M, Rakvag TN, Klepstad P et al.: Sequence variations in the UDP-glucuronosyltransferase 2137 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenomics J. 3(1), 17-26 (2003).
64. Sawyer MB, Innocenti F, Das S et al.: A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine. Clin. Pharmacol. Ther. 73(6), 566-574 (2003).
65. Saeki M, Saito Y, Jinno H et al.: Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab. Dispos. 32(9), 1048-1054 (2004).
66. Daly AK, Aithal GP, Leathart JB, Swainsbury RA, Dang TS, Day CP: Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132(1), 272-281 (2007).
67. Levesque E, Delage R, Benoit-Biancamano MO et al.: The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin. Pharmacol. Ther. 81(3), 392-400 (2007).
68. Coffman BL, King CD, Rios GR, Tephly TR: The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab. Dispos. 26(1), 73-77 (1998).
69. Coulbault L, Beaussier M, Verstuyft C et al.: Environmental and genetic factors associated with morphine response in the postoperative period. Clin. Pharmacol. Ther. 79(4), 316-324 (2006).
70. Ross JR, Rutter D, Welsh K et al.: Clinical response to morphine in cancer patients and genetic variation in candidate genes. Pharmacogenomics J. 5(5), 321-336 (2005).
71. Duguay Y, Baar C, Skorpen F, Guillemette C: A novel functional polymorphism in the uridine diphosphate- glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin. Pharmacol. Ther. 75(3), 223-233 (2004).
72. Darbari DS, van Schaik RH, Capparelli EV, Rana S, McCarter R, van den Anker J: UGT2B7 promoter variant -840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell disease. Am. J. Hematol. 83(3), 200-202 (2008).
73. Hirota T, Ieiri I, Takane H, Sano H et al.: Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab. Dispos. 31(5), 677-680 (2003).
74. Assael BM: Pharmacokinetics and drug distribution during postnatal development. Pharmacol. Ther. 18(2), 159-197 (1982).
75. Choonara IA, McKay P, Hain R, Rane A: Morphine metabolism in children. Br. J. Clin. Pharmacol. 28(5), 599-604 (1989).
76. Anderson BJ, McKee AD, Holford NH: Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin. Pharmacokinet. 33(5), 313-327 (1997).
77. Pacinci GM, Sawe J, Kager L, Rane A: Morphine glucuronidation in human fetal and adult liver. Eur. J. Clin. Pharmacol. 22(6), 553-558 (1982).
78. de Wildt SN, Kearns GL, Leeder JS, van den Anker JN: Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin. Pharmacokinet. 36(6), 439-452 (1999).
79. McCarver DG, Hines RN: The ontogeny of human drug-metabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther. 300(2), 361-366 (2002).
80. Strassburg CP, Strassburg A, Kneip S et al.: Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50(2), 259-265 (2002).
81. Zaya MJ, Hines RN, Stevens JC: Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab. Dispos. 34(12), 2097-2101 (2006).
82. Somogyi AA, Barratt DT, Coller JK: Pharmacogenetics of opioids. Clin. Pharmacol. Ther. 81(3), 429-444 (2007).
83. Syvanen S, Xie R, Sahin S, Hammarlund-Udenaes M: Pharmacokinetic consequences of active drug efflux at the blood-brain barrier. Pharm. Res. 23(4), 705-717 (2006).
84. +/+) mice. Br. J. Pharmacol. 128(3), 563-568 (1999).
85. Bourasset F, Scherrmann JM: Carrier-mediated processes at several rat brain interfaces determine the neuropharmacokinetics of morphine and morphine-6-β-D-glucuronide. Life Sci. 78(20), 2302-2314 (2006).
86. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin. Pharmacol. Ther. 74(6), 543-554 (2003).
87. Drewe J, Ball HA, Beglinger C et al.: Effect of P-glycoprotein modulation on the clinical pharmacokinetics and adverse effects of morphine. Br. J. Clin. Pharmacol. 50(3), 237-246 (2000).
88. Kim RB, Leake BF, Choo EF et al.: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70(2), 189-199 (2001).
89. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadee W: Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet. Genomics 15(10), 693-704 (2005).
90. Campa D, Gioia A, Tomei A, Poli P, Barale R: Association of ABCB1/ MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther. 83(4), 559-566 (2008).
91. Mantione KJ, Goumon Y, Esch T, Stefano GB: Morphine 6β glucuronide: fortuitous morphine metabolite or preferred peripheral regulatory opiate? Med. Sci. Monit. 11(5), MS43-MS46 (2005).
92. Bourasset F, Cisternino S, Temsamani J, Scherrmann JM: Evidence for an active transport of morphine-6-β-D-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J. Neurochem. 86(6), 1564-1567 (2003).
93. Carrupt PA, Testa B, Bechalany A, el Tayar N, Descas P, Perrissoud D: Morphine 6-glucuronide and morphine 3-glucuronide as molecular chameleons with unexpected lipophilicity. J. Med. Chem. 34(4), 1272-1275 (1991).
94. Yamada H, Ishii K, Ishii Y, Ieiri I, Nishio S, Morioka T et al.: Formation of highly analgesic morphine-6-glucuronide following physiologic concentration of morphine in human brain. J. Toxicol. Sci. 28(5), 395-401 (2003).
95. Gao B, Hagenbuch B, Kullak-Ublick GA, Benke D, Aguzzi A, Meier PJ: Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier. J Pharmacol. Exp. Ther. 294(1), 73-79 (2000).
96. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ: Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178(64), 984-986 (1972).
97. Way WL, Costley EC, Leongway E: Respiratory sensitivity of the newborn infant to meperidine and morphine. Clin. Pharmacol. Ther. 6454-461 (1965).
98. Koren G, Butt W, Chinyanga H, Soldin S, Tan YK, Pape K: Postoperative morphine infusion in newborn infants: assessment of disposition characteristics and safety. J. Pediatr. 107(6), 963-967 (1985).
99. Rai A, Bhalla S, Rebello SS, Kastrissios H, Gulati A: Disposition of morphine in plasma and cerebrospinal fluid varies during neonatal development in pigs. J. Pharm. Pharmacol. 57(8), 981-986 (2005).
100. Bragg P, Zwass MS, Lau M, Fisher DM: Opioid pharmacodynamics in neonatal dogs: differences between morphine and fentanyl. J. Appl. Physiol. 79(5), 1519-1524 (1995).
101. Bouwmeester NJ, Hop WC, van Dijk M, Anand KJ, van den Anker JN, Tibboel D: Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. Intensive Care Med. 29(11), 2009-2015 (2003).
102. Bouwmeester NJ, Anderson BJ, Tibboel D, Holford NH: Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br. J. Anaesth. 92(2), 208-217 (2004).
103. Hain RD, Hardcastle A, Pinkerton CR, Aherne GW: Morphine and morphine-6-glucuronide in the plasma and cerebrospinal fluid of children. Br. J. Clin. Pharmacol. 48(1), 37-42 (1999).
104. Gill AM, Cousins A, Nunn AJ, Choonara IA: Opiate-induced respiratory depression in pediatric patients. Ann. Pharmacother. 30(2), 125-129 (1996).
105. Tsai C, Ahdab-Barmada M, Daood MJ et al.: P-glycoprotein expression in the developing human central nervous system: cellular and tissue localization. Pediatr. Res. 47436A (2000).
106. Watchko JF, Daood MJ, Mahmood B, Vats K, Hart C, Ahdab-Barmada M: P-glycoprotein and bilirubin disposition. J. Perinatol. 21(Suppl. 1), S43-S47; discussion S59-S62 (2001).
107. Mayer P, Hollt V: Pharmacogenetics of opioid receptors and addiction. Pharmacogenet. Genomics 16(1), 1-7 (2006).
108. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W: Allelic expression imbalance of human μ opioid receptor (OPRM1) caused by variant A118G. J. Biol. Chem. 280(38), 32618-32624 (2005).
109. Klepstad P, Rakvag TT, Kaasa S et al.: The 118 A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol. Scand. 48(10), 1232-1239 (2004).
110. Beyer A, Koch T, Schroder H, Schulz S, Hollt V: Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human μ-opioid receptor. J. Neurochem. 89(3), 553-560 (2004).
111. Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL: A single nucleotide polymorphic mutation in the human μ-opioid receptor severely impairs receptor signaling. J. Biol. Chem. 276(5), 3130-3137 (2001).
112. Oertel BG, Schmidt R, Schneider A, Geisslinger G, Lotsch J. The μ-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet. Genomics 16(9), 625-636 (2006).
113. Reyes-Gibby CC, Shete S, Rakvag T et al.: Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain 130(1-2), 25-30 (2007).
114. Romberg RR, Olofsen E, Bijl H et al.: Polymorphism of μ-opioid receptor gene (OPRM1:c. 118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology 102(3), 522-530 (2005).
115. Lotsch J, Skarke C, Grosch S, Darimont J, Schmidt H, Geisslinger G: The polymorphism A118G of the human μ-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics 12(1), 3-9 (2002).
116. Bhat R, Chari G, Rao R: Effects of prenatal cocaine, morphine, or both on postnatal opioid (μ) receptor development. Life Sci. 78(13), 1478-1482 (2006).
117. Zubieta JK, Heitzeg MM, Smith YR et al.: COMT val158met genotype affects μ-opioid neurotransmitter responses to a pain stressor. Science 299(5610), 1240-1243 (2003).
118. Diatchenko L, Nackley AG, Slade GD et al.: Catechol-O-methyltransferase gene polymorphisms are associated with multiple pain-evoking stimuli. Pain 125(3), 216-224 (2006).
119. Diatchenko L, Slade GD, Nackley AG et al.: Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum. Mol. Genet. 14(1), 135-143 (2005).
120. Lundstrom K, Salminen M, Jalanko A, Savolainen R, Ulmanen I: Cloning and characterization of human placental catechol-O-methyltransferase cDNA. DNA Cell Biol. 10(3), 181-189 (1991).
121. Bertocci B, Miggiano V, Da Prada M, Dembic Z, Lahm HW, Malherbe P: -Human catechol-O-methyltransferase: cloning and expression of the membrane-associated form. Proc. Natl Acad. Sci. USA 88(4), 1416-1420 (1991).
122. Rakvag TT, Klepstad P, Baar C et al.: The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain 116(1-2), 73-78 (2005).
123. Williams DG, Dickenson A, Fitzgerald M, Howard RF: Developmental regulation of codeine analgesia in the rat. Anesthesiology 100(1), 92-97 (2004).
124. Eddy NB, Friebel H, Hahn KJ, Halbach H: Codeine and its alternates for pain and cough relief. I. Codeine, exclusive of its antitussive action. Bull. World Health Organ. 38(5), 673-741 (1968).
125. von Muhlendahl KE, Scherf-Rahne B, Krienke EG, Baukloh G: Codeine intoxication in childhood. Lancet 2 (7980), 303-305 (1976).
126. American Academy of Pediatrics, Committee on Drugs: Use of codeine and dextromethorphan-containing cough remedies in children. Pediatrics 99(6), 918-920 (1997).
127. Sachdeva DK, Stadnyk JM: Are one or two dangerous? Opioid exposure in toddlers. J. Emerg. Med. 29(1), 77-84 (2005).
128. Meyer D, Tobias JD: Adverse effects following the inadvertent administration of opioids to infants and children. Clin. Pediatr. (Phila), 44(6), 499-503 (2005).
129. Magnani B, Evans R: Codeine intoxication in the neonate. Pediatrics 104(6), E75 (1999).
130. Talbott GA, Lynn AM, Levy FH, Zelikovic I: Respiratory arrest precipitated by codeine in a child with chronic renal failure. Clin. Pediatr. (Phila.) 36(3), 171-173 (1997).
131. Raue W: Life poisoning with codeine-containing cough syrup. Z. Arztl. Fortbild. (Jena). 60(6), 353-354 (1966).
132. Rumler W, Weigel W: On codeine poisoning in childhood. A problem of the pharmacology and toxicology of the growing body. Monatsschr. Kinderheilkd. 111, 241-246 (1963).
133. American Academy of Pediatrics, Committee on Drugs: Use of codeine- and dextromethorphan-containing cough syrups in pediatrics. Pediatrics 62(1), 118-122 (1978).
134. Chang AB, Glomb WB: Guidelines for evaluating chronic cough in pediatrics: ACCP evidence-based clinical practice guidelines. Chest 129(Suppl. 1), S260-S283 (2006).
135. Taylor JA, Novack AH, Almquist JR, Rogers JE: Efficacy of cough suppressants in children. J. Pediatr. 122(5 Pt 1), 799-802 (1993).
136. Reid KJ Jr: Questions concerning cough preparation statement by the AAP Committee on Drugs. Pediatrics 102(3 Pt 1), 661 (1998).
137. Maulik SK, Maulik M: Pharmacological control of cough. Indian J. Pediatr. 68(Suppl. 2) S33-S38 (2001).
138. Ng DK, Tong TF, Chan CH: Prescription of codeine in young infants. Hong Kong Med. J. 10(6), 439-440 (2004).
139. Lee AC, Chan R, So KT: A case of probable codeine poisoning in a young infant after the use of a proprietary cough and cold medicine. Hong Kong Med. J. 10(4), 285-287 (2004).
140. Tong TF, Ng KK: Codeine ingestion and apparent life-threatening event in a neonate. Pediatr. Int. 43(5), 517-518 (2001).
141. Madadi P, Ross CJD, Carleton BC et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin. Pharmacol. Ther. (2008) (In press).
142. Davis JM, Bhutani VK: Neonatal apnea and maternal codeine use. Pediatr. Res. 19(4 Pt 2), 170A (1985).
143. Naumburg EG, Meny RG: Unexplained neonatal apnea, bradycardia, cyanosis: an association with opioids in breast milk. Clin. Res. 35(1), A79 (1987).
144. Smith J: Codeine-induced bradycardia in a breast-fed infant. Clin. Res. 30(2), A259 (1982).
145. Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G: Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am. J. Obstet. Gynecol. 168(5), 1393-1399 (1993).
146. Williams DG, Patel A, Howard RF: Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability. Br. J. Anaesth. 89(6), 839-845 (2002).
147. Brousseau DC, McCarver DG, Drendel AL, Divakaran K, Panepinto JA: The effect of CYP2D6 polymorphisms on the response to pain treatment for pediatric sickle cell pain crisis. J. Pediatr. 150(6), 623-626 (2007).
148. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson B: Acute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood 89(5), 1787-1792 (1997).
149. Lane PA: Sickle cell disease. Pediatr. Clin. North Am. 43(3), 639-664 (1996).
150. Mignat C, Wille U, Ziegler A: Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes. Life Sci. 56(10), 793-799 (1995).